Thromb Haemost 1975; 34(01): 106-114
DOI: 10.1055/s-0038-1651450
Original Article
Schattauer GmbH

Effect of Anabolic Steroids on Plasma Antithrombin III

α2 Macroglobulin and α1 Antitrypsin Levels
I. D Walker
1   Department of Haematology, Royal Infirmary, Glasgow
,
J. F Davidson
1   Department of Haematology, Royal Infirmary, Glasgow
,
P Young
1   Department of Haematology, Royal Infirmary, Glasgow
,
J. A Conkie
1   Department of Haematology, Royal Infirmary, Glasgow
› Author Affiliations
Further Information

Publication History

Received 17 February 1975

Accepted 24 March 1975

Publication Date:
02 July 2018 (online)

Summary

The effect of seven different anabolic steroids (Ethyloestrenol, Methenolone acetate, Norethandrolone, Methylandrostenediol, Oxymetholone, Methandienone, and Stanozolol) on three α-globulin antiprotease inhibitors of thrombin and plasmin was studied in men with ischaemic heart disease. In distinct contrast to the oral contraceptives, five of the six 17-α-alkylated anabolic steroids studied produced increased plasma Antithrombin III levels and five produced decreased levels of plasma α2-macroglobulin. The effect on plasma α1antitrypsin levels was less clear-cut but three of the steroids examined produced significantly elevated levels. The increased plasma fibrinolytic activity which the 17-α-alkylated anabolic steroids induce is therefore unlikely to be secondary to disseminated intravascular coagulation.

 
  • References

  • 1 Abildgaard U. 1967; Purification of two progressive antithrombin’s of human plasma. Scandinavian Journal of Clinical and Laboratory Investigation 19: 190.
  • 2 Abildgaard U. 1971; Antithrombin III, an important physiological inhibitor of coagulation. Farmakoterapi (Oslo) 27: 22.
  • 3 Barbosa J, Seal TT. S, and Doe R. P. 1971; Effects of anabolic steroids on Haptoglobin, Grosomucoid, Plasminogen, Fibrinogen, Transferrin, Ceruloplasmin, 1 antitrypsin, β glucuronidase and total serum proteins. Journal of Clinical Endocrinology 33: 388.
  • 4 Chakrabarti R, Hocking E. D, Fearnley G. R, Mann R. D, Attwell T. N, and Jackson D. 1968; Fibrinolytic activity and Coronary-artery disease. Lancet I: 987.
  • 5 Davidson J. F, Lochhead M, McDonald G. A, and McNicol G. P. 1972; Fibrinolytic enhancement by Stanozolol; A double blind trial. British Journal of Haematology 22: 543.
  • 6 Dixon W. J, and Massey F. J. 1957. Introduction to Statistical Analysis. 2nd edition. McGraw Book Company Incorporated;
  • 7 Egeberg O. 1965; Inherited Antithrombin Deficiency causing Thrombophilia. Thrombosis et Diathesis Haemorrhagica 13: 516.
  • 8 Fagerhol M. K, Abildgaard U, Bergsjo P, and Jacobsen J. H. 1970; Oral Contraceptives and low Antithrombin III concentration (Letter). Lancet I: 1175.
  • 9 Ganrot P. O. 1967; Interaction of plasmin and trypsin with α2 macroglobulin. Acta Chemica Scandinavia 21: 602.
  • 10 Ganrot P. O. 1969; Electrophoretic Separation of two Thrombin Inhibitors in plasma and Serum. Scandinavian Journal of Clinical and Laboratory Investigation 24: 11.
  • 11 Haverback B. J, Dyce B, Bundy H. F, Wirtshafter S. K, and Edmondson H. A. 1962; Protein binding of pancreatic proteolytic enzymes. Journal of Clinical Investigation 41: 972.
  • 12 Horne C. H. W, Howie P. W, Weir R. J, and Goudie R. B. 1970; Effects of Combined Oestrogen-progestogen oral contraceptive on serum levels of oc2 macroglobulin, transferrin, albumin and IgG. Lancet I: 49.
  • 13 Lanchantin G. F, Plesset M. L, Friedmann J. A, and Hart D. W. 1966; Dissociation of esterolytic and clotting activities of thrombin by trypsin-binding macro-globulin. Proceedings of the Society for Experimental Biology and Medicine 121: 444.
  • 14 Laurell C.-B, Ktjllander S, and Thorell J. 1968; Effect of administration of a combined oestrogen-progestin contraceptive on the level of individual plasma proteins. Scandinavian Journal of Clinical and Laboratory Investigation 21: 337.
  • 15 Mehl J. W, O’Connell W, and De Groot J. 1964; Macroglobulin from human plasma which forms an enzymatically active compound with trypsin. Science 145: 821.
  • 16 Murano G. 1973 Personal Communication.
  • 17 Nilsson I. M, Hedner U, and Isacson S. 1974. Phenformin and Ethyloestrenol in recurrent venous thrombosis. In: Davidson. (ed.) Proceedings of the 2nd International Congress on Synthetic Fibrinolytic Agents. Paris: 30th Sept.-1st October, 1974 (in Press).
  • 18 Odegard O. R, Abildgaard U, and Fagerhol M. C. 1973 Antithrombin III related to the degree of hypercoagulation. Proceedings 4th Congress International Society Thrombosis and, Haemostasis. Vienna: 1973 (abst) 225.
  • 19 Porter P, Porter M. C, and Shanberge J. M. 1967; Heparin cofactor and plasma antithrombin in relation to the mechanism of inactivation of thrombin by heparin. Clinica Chimica Acta 17: 189.
  • 20 Ratnoff O. D, Pensky J, Ogston D, and Naff G. B. 1969; The inhibition of plasmin, plasma Kallikrein, plasma permeability factor and the C1 subcomponent of the first component of complement by serum C1 esterase inhibitor. Journal of Experimental Medicine 129: 315.
  • 21 Rimon A, Shamash Y, and Shapiro B. 1966; The plasmin inhibitor of human plasma, iv. Its action on plasmin, trypsin, chymotrypsin, and thrombin. Journal of Biological Chemistry 241: 5102.
  • 22 Schwick H. G, Heimburger N, and Haupt H. 1967; Purification of chemico physical properties of some proteinase inhibitors of plasma. Thrombosis et Diathesis Haemor-rhagica 18: 302.
  • 23 von Kaulla E, Droegemueller W, Aoki N, and von Kaulla K. N. 1971; Antithrombin III depression and thrombin generation acceleration in women taking oral contraceptives. American Journal of Obstetrics and Gynaecology 109: 869.
  • 24 Yin E. T, Wessler S, and Still P. J. 1971; Identity of plasma activated factor X inhibitor with antithrombin III and heparin cofactor. Journal of Biological Chemistry 246: 3712.